Due to low commercial sales, Abbott stopped selling the first-generation Absorb Bioresorbable Vascular Scaffold. We pioneered bioresorbable technology because we believe it offers patients the possibility of life without permanent metallic implants, and we will continue work on a next generation bioresorbable device. We'll also continue to follow implanted patients in existing Absorb clinical trials to assess long-term outcomes after the scaffold has dissolved. We're dedicated to developing treatments that help patients with vascular and other heart diseases live their fullest lives.
Q1. What is the announcement?
Due to low commercial uptake, Abbott stopped selling its first-generation Absorb Bioresorbable Vascular Scaffold. Abbott discontinued all sizes of Absorb Bioresorbable Vascular Scaffold System and Absorb GT1 Bioresorbable Vascular Scaffold System as of September 14th 2017. We recognize that BRS technologies offer patients the possibility of life without permanent metallic implants, and we will continue to work on a next generation device while monitoring long-term outcomes after stent resorption in current Absorb trials.
Q2. Does this decision apply to all the geographies?
Yes. Abbott discontinued the Absorb Bioresorbable Vascular Scaffold System and Absorb GT1 Bioresorbable Vascular Scaffold System as of September 14th in all countries.
Q3. What should physicians do with the existing product?
Physicians can implant Absorb with their available inventory if they choose to do so.
Q4. Will Absorb continue to be studied in clinical trials?
Abbott will continue to follow patients in existing clinical studies per protocols.
If you need more information, please contact your local Abbott Vascular representative or customer service team.
AP2946433-WBO Rev. A
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.